-
Mashup Score: 4
PURPOSE Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL. METHODS Thirty-eight institutions participated in the Global nLPHL One Working Group retrospective study of NLPHL cases from 1992 to 2021. We measured progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death rate. We performed uni- and multivariable (MVA) Cox regression stratified by management to select factors for the lymphocyte-predominant international prognostic score (LP-IPS) validated by five-fold cross-validation. RESULTS We identified 2,243 patients with a median age of 37 years (IQR, 23-51). The median follow-up was 6.3 years (IQR, 3.4-10.8). Most had stage I to II (72.9%) and few B symptoms (9.9%) or splenic involvement (5.4%). IAP was scored
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5
Recent research has shown encouraging results for older patients with classical Hodgkin lymphoma treated with Adcetris plus chemotherapy or Opdivo.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 1Big Data and Collaboration: A Case Study on Improving Outcomes in Hodgkin Lymphoma | Docwire News - 3 month(s) ago
Dr. Chadi Nabhan is joined by esteemed guests from the HoLISTIC consortium to discuss Hodgkin lymphoma.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2The Latest in Hodgkin Treatments 2024: Patient Event Registration - 3 month(s) ago
Join Hodgkin lymphoma experts discussing the latest treatments, symptom relief, personalized care, sequencing, better monitoring, and hope.
Source: thepatientstory.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 8
Mazyar Shadman, MD, MPH, and the Oncology Brothers discuss recent data from SWOG S1826 on nivolumab-AVD in patients aged 60 years and older with advanced stage Hodgkin lymphoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
Mazyar Shadman, MD, MPH, and the Oncology Brothers discuss recent data from SWOG S1826 on nivolumab-AVD in patients aged 60 years and older with advanced stage Hodgkin lymphoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Hodgkin Lymphoma - Cancer Stat Facts - 5 month(s) ago
Hodgkin Lymphoma statistics
Source: seer.cancer.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Hodgkin Lymphoma - Mitigating Toxicity While Preserving Cure - Eight Year Data from MIOT International, Chennai, India - 5 month(s) ago
BackgroundOne of the most treatable cancers, Hodgkin’s lymphoma (HL), has a 5-year survival rate of approximately 85%.We still see relapse and refract…
Source: www.sciencedirect.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0Relapse Refractory Hodgkin lymphoma [slides 2023] - 7 month(s) ago
By: Allen Wilbanks Date: September 27/2023 Swetha Kambhampati, MD, presented at a conference with gratitude to the organizers and Dr. Flowers for the opportunity. She discussed innovative approaches for relapse refractory Hodgkin lymphoma. Dr. Kambhampati outlined her talk, covering BV and PD-1 inhibitors as salvage…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🩺 Swetha Kambhampati, MD, delivered an enlightening talk at the conference today, shedding light on cutting-edge approaches for relapse refractory #HodgkinLymphoma 👥 @_MDEducation @Ryan_Fitzpatric @cityofhope [video]: https://t.co/uMp0SaXbx7 https://t.co/mkW2wfBoUA
-
-
Mashup Score: 0
Nivolumab plus brentuximab vedotin, followed by ISRT, appears safe and effective for low-risk, relapsed classical Hodgkin lymphoma.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
SCI members @michaelsbinkley, Richard Hoppe & others develop the lymphocyte-predominant international prognostic score to identify high-risk patients & inform upcoming prospective clinical trials for patients with low scores. https://t.co/OsHQtr7SnC #HodgkinLymphoma https://t.co/odg6KoJVhY